All In Biotech

Drug Trial Radar · NCT07551349

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

An Open-Label, Multicenter, Phase 1/2 Study of Allogeneic Dual-target CD70/CAIX (CA9) Chimeric Antigen Receptor Natural Killer Cells in Adults With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Apr 14, 2027

Study completion Apr 17, 2028

Sponsor

Lead sponsor
Beijing BiotechIndustry
Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therapy. The study is designed to determine a recommended dose and schedule, characterize hepatobiliary safety, and explore whether CD70-high, CAIX-high, or dual-high tumors derive the greatest benefit. Biomarker-defined activity signals will be used to guide whether later development should prioritize CD70, CAIX/CA9, or continued dual-targeting.

Conditions

  • Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Interventions

  • EB-701/CA9-NKBiological

    dual-target allogeneic CAR-NK cells (single infusion on Day 0; optional second infusion on Day 15 if safety criteria are met)

  • FludarabineDrug

    lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs)Time frame: 28 Days
  2. Determination of recommended phase 2 doseTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.